1601O
3-year survival with neoadjuvant-adjuvant pembrolizumab from SWOG S1801

1600O
Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a Ph 1 trial